Sponsor

Xencor, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Xencor, Inc. appears in 12 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials12
Recruiting shown3
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

12 shown
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune DiseasesNCT07284797 · lead sponsor · 2026-02-24
RECRUITING
A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid ArthritisNCT07230353 · lead sponsor · 2025-10-21
RECRUITING
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaNCT05433142 · lead sponsor · 2022-06-13
RECRUITING
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCNCT06173505 · lead sponsor · 2023-12-27
TERMINATED
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsNCT05585034 · lead sponsor · 2022-12-14
COMPLETED
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesNCT05032040 · lead sponsor · 2022-07-21
ACTIVE_NOT_RECRUITING
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerNCT05005728 · lead sponsor · 2021-10-22
COMPLETED
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung CancerNCT04590781 · lead sponsor · 2021-05-10
TERMINATED
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469 · lead sponsor · 2019-05-29
COMPLETED
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398 · lead sponsor · 2019-05-01
COMPLETED
A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488 · lead sponsor · 2018-07-10
COMPLETED
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate CancerNCT05733351 · collaborator · 2023-08-03
TERMINATED

Drugs studied in this sponsor's trials

3 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Xencor, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
abiraterone1
docetaxel1
enzalutamide1

Sponsor roles

lead sponsor11
collaborator1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.